TheEdgeResearch
Home / Stocks / CBDL

CBD Life Sciences Inc. (CBDL)

OTC Healthcare Drug Manufacturers - Specialty & Generic
$0.00 ▼ -50.00%
Market Cap
$187,697
Sector
Healthcare
Industry
Drug Manufacturers - Specialty & Generic
Beta
-3603.52
52-Wk Range
0.0001-0.001
CEO
Lisa Anne Nelson
Country
US
Currency
USD

CBD Life Sciences Inc. operates in the Drug Manufacturers - Specialty & Generic industry of the Healthcare sector, headquartered in Scottsdale, AZ, US. The stock last traded at $0.00, down 50.00% on the session, giving a market capitalisation of $187,697. On trailing twelve-month figures it carries a trailing P/E of -14.93, a net margin of -40.0%. Its beta of -3603.52 implies it has historically moved less than the broad market.

Valuation & profitability (TTM)
P/E
-14.93
Price / Sales
2.73
Price / Book
0.54
EV / EBITDA
2.27
Gross margin
7.8%
Operating margin
-124.8%
Net margin
-40.0%
Return on equity
Debt / equity
0.00
Current ratio
15.12
Dividend yield
0.0%
Payout ratio
0.0%
Company profile
Exchange
Other OTC
Employees
3
IPO date
2009-09-11
Headquarters
Scottsdale, AZ, US
About CBD Life Sciences Inc.

CBD Life Sciences Inc. specializes in formulating and distributing a broad array of organic items infused with cannabidiol. Their extensive range of natural CBD offerings includes hemp tinctures, topical massage oils, targeted recovery and pain relief balms, dietary aids to support anxiety and restful sleep, various consumable treats, and a dedicated collection of products for animal companions. The company's principal operations are conducted from Scottsdale, Arizona.

Comparable companies

CBD Life Sciences Inc. is most often compared with the following Healthcare names:

AOXGETBIGPFTHPMMIVIXFJUVAFLRSVNEPTFRMRKSHWZ
More research on CBDL
CBDL technical analysis CBDL TheEdge Score Compare against peers
Open full interactive analysis & DCF →